Rani Therapeutics
RANI
22 hedge funds and large institutions have $20.3M invested in Rani Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
47% more funds holding
Funds holding: 15 → 22 (+7)
4% more capital invested
Capital invested by funds: $19.6M → $20.3M (+$725K)
0.73% more ownership
Funds ownership: 5.57% → 6.3% (+0.73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.6M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$945K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$479K |
| 4 |
JP Morgan Chase
New York
|
+$95.1K |
| 5 |
Morgan Stanley
New York
|
+$85.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$1.39M |
| 2 |
Goldman Sachs
New York
|
-$1.08M |
| 3 |
Millennium Management
New York
|
-$517K |
| 4 |
CH
Canton Hathaway
Providence,
Rhode Island
|
-$114K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$18K |
RANI Hedge Fund Activity: Q4 2021 in Review
22 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2021, worth a combined $20.3M — up 3.7% from $19.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RANI positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.6M. The largest seller was CAAS Capital Management, cutting an estimated $1.39M.
- 22 institutional investors held Rani Therapeutics (RANI) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $20.3M of Rani Therapeutics stock for Q4 2021, up 3.7% quarter-over-quarter.
- 10 funds opened new Rani Therapeutics positions in Q4 2021 and 3 closed out, a net change of +7 holders.
- The largest Rani Therapeutics buyer in Q4 2021 was BlackRock, an estimated $2.6M added.
- The largest Rani Therapeutics seller in Q4 2021 was CAAS Capital Management, an estimated $1.39M sold.
Based on aggregated 13F filings for Q4 2021.